Startups

BioBots rebrands as Allevi in a push for the software space

The startup, makers of desktop 3D printers for living cells, has also parted ways with cofounder Danny Cabrera.

Adios, BioBots. Hello, Allevi. (Courtesy photo)

Don’t call it BioBots anymore: Allevi is the new name of the Pennovation-based startup, makers of a 3D printer for live tissue, that is now making a play for the software space in addition to its hardware offering.

The company, which moved its team of 10 to Pennovation in February, parted ways with cofounder Danny Cabrera, who left the startup in August and is working on a San Francisco-based project around genetic engineering.

Cofounder Ricky Solorzano is now the CEO of the company under its new banner. The Penn grad is leading the startup as it raises another round of capital, a follow-up to the $1.25 million the company took on in 2015 from DreamIt Ventures500 Startups and Ben Franklin Technology Partners.

While the 3D printers have been the focus of the startup’s offering thus far, Solorzano said under the Allevi name it would focus on selling a joint offer of software and materials, without ceasing production of the hardware.

“So far, the challenge has been that people don’t actually know why bioprinters are useful,” the CEO said. “We’ve gathered a user base that’s now excited about the ability to experiment with the platform. All of a sudden it has created more ideas for bioprinting that weren’t available before.”

Now, for clarity’s sake: BioBots did provide accompanying software with its printers before. Solorzano said the newly-released offering is more complete and will let users remove the complexity while optimizing scientist’s workflow. Here’s a jargon-laden walkthrough of the software platform:

https://www.youtube.com/watch?v=atwfSxEbqmc

“The workflow allows you to setup 12 experiments at once and that’s a big timesaver,” Solorzano said.

The company says its new workflow setup lets scientists complete in three to four days what normally might take a month.

“We couldn’t be more excited to have a single direction, being laser-focused and knowing what our strengths are,” said Solorzano. “Having everyone on board this ship for that is so exciting.”

Companies: BioBots

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

What actually is the 'creator economy'? Here's why we should care

Celebrate Philly’s winners of the 2024 Technical.ly Awards

Skills, not schools: A new path for government tech

An interactive timeline of Philly’s tech ecosystem in 2024

Technically Media